CTLA4 and cancer: The development of cancer immunotherapy in clinical practice initiated from immune checkpoint inhibitors (ICIs), especially ipilimumab, an anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody [5].